PMID- 33550476
OWN - NLM
STAT- MEDLINE
DCOM- 20210423
LR  - 20220531
IS  - 1434-4726 (Electronic)
IS  - 0937-4477 (Linking)
VI  - 278
IP  - 5
DP  - 2021 May
TI  - LncRNA FEZF1-AS1 accelerates the migration and invasion of laryngeal squamous 
      cell carcinoma cells through miR-4497 targeting GBX2.
PG  - 1523-1535
LID - 10.1007/s00405-021-06636-5 [doi]
AB  - BACKGROUND: MiR-4497 has been previously proved to exert an anti-cancer role in 
      laryngeal squamous cell carcinoma (LSCC) by negatively regulating gastrulation 
      brain homeobox 2 (GBX2). However, the mechanism of miR-4497 in LSCC has yet to be 
      fully elucidated. This study intended to investigate the role of FEZF1-AS1 in the 
      migration and invasion of LSCC cells and clarified its mechanism through miR-4497 
      and GBX2. METHODS: qPCR evaluated the expression of FEZF1-AS1, miR-4497 and GBX2 
      in LSCC tissues and cells, compared with controls. Western blotting analyzed 
      GBX2, E-cadherin, N-cadherin and Vimentin. CCK8, wound healing and transwell 
      assays assessed the viability, migration and invasion of TU686 and UM-SCC-17A 
      cells. Luciferase reporter assay affirmed the interplay of miR-4497 with 
      FEZF1-AS1 or GBX2 and Pearson's correlation analysis explored the association 
      between each two genes in both tumor and non-tumor tissues. RESULTS: FEZF1-AS1 
      was highly expressed in LSCC tissues and cells. Silence or elevation of FEZF1-AS1 
      inhibited or promoted the migration and invasion of TU686 and UM-SCC-17A cells. 
      FEZF1-AS1 targeted and negatively modulated miR-4497. Inhibition of miR-4497 
      markedly restored the FEZF1-AS1 silence-repressed cell viability of TU686 and 
      UM-SCC-17A cells. Further, FEZF1-AS1 could positively regulate GBX2 via negative 
      regulation of miR-4497. In these two cells, GBX2 deficiency reversed the 
      promoting impacts of miR-4497 repression on migration and invasion. CONCLUSION: 
      Taken together, FEZF1-AS1, heightened in LSCC tissues and cells, promotes cell 
      migration and invasion of LSCC cells via targeting miR-4497 that inhibits GBX2. 
      The finding may offer new options for the treatment of this cancer.
FAU - Chen, Xudong
AU  - Chen X
AUID- ORCID: 0000-0002-1673-4696
AD  - Department of Otolaryngology, First Hospital of Ningbo City, Ningbo, Zhejiang, 
      315000, People's Republic of China. chenxudong_xdc@163.com.
FAU - Cheng, Peng
AU  - Cheng P
AD  - Department of Otolaryngology, First Hospital of Ningbo City, Ningbo, Zhejiang, 
      315000, People's Republic of China.
FAU - Hu, Cihao
AU  - Hu C
AD  - Department of Otolaryngology, First Hospital of Ningbo City, Ningbo, Zhejiang, 
      315000, People's Republic of China.
LA  - eng
GR  - 2020360873/the Medical and Health Project of Zhejiang Province/
PT  - Journal Article
DEP - 20210207
PL  - Germany
TA  - Eur Arch Otorhinolaryngol
JT  - European archives of oto-rhino-laryngology : official journal of the European 
      Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the 
      German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
JID - 9002937
RN  - 0 (GBX2 protein, human)
RN  - 0 (Homeodomain Proteins)
RN  - 0 (MIRN4497 microRNA, human)
RN  - 0 (MicroRNAs)
RN  - 0 (RNA, Long Noncoding)
SB  - IM
MH  - Cell Proliferation
MH  - *Head and Neck Neoplasms
MH  - Homeodomain Proteins
MH  - Humans
MH  - *MicroRNAs/genetics
MH  - *RNA, Long Noncoding
MH  - Squamous Cell Carcinoma of Head and Neck/genetics
OTO - NOTNLM
OT  - FEZF1-AS1
OT  - GBX2
OT  - Invasion
OT  - Laryngeal squamous cell carcinoma
OT  - Migration
OT  - miR-4497
EDAT- 2021/02/08 06:00
MHDA- 2021/04/24 06:00
CRDT- 2021/02/07 20:52
PHST- 2020/10/14 00:00 [received]
PHST- 2021/01/20 00:00 [accepted]
PHST- 2021/02/08 06:00 [pubmed]
PHST- 2021/04/24 06:00 [medline]
PHST- 2021/02/07 20:52 [entrez]
AID - 10.1007/s00405-021-06636-5 [pii]
AID - 10.1007/s00405-021-06636-5 [doi]
PST - ppublish
SO  - Eur Arch Otorhinolaryngol. 2021 May;278(5):1523-1535. doi: 
      10.1007/s00405-021-06636-5. Epub 2021 Feb 7.